FGFR1 Overexpression

CI-VAR-00003196Explore in graph →CIViC 2904

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Urothelial Carcinoma1
FGFR1 Overexpression	(prognostic)	Prognostic	D	Supports Poor Outcome	4	submitted	EID9582 Two types of UC cell lines were compared in this study. T24 and J82 which are mesenchymal subtype and overexpress FGFR1, and RT-4 and UMUC-14, epithelial subtype which do not express FGFR1. T24 and J8… (full text at CIViC) PMID 30326563 · Kim et al., 2018 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
FGFR1 Overexpression	Fexagratinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7952 Study of FGFR1 inhibitor AZD4547 in NSCLC xenograft models. FGFR1-amplified models that overexpress FGFR1 (detected by IHC) were strongly inhibited by 25mg/kg AZH4547 (P≤0.0001). Another FGFR1-ampli… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Lung Neoplasm1
FGFR1 Overexpression	Docetaxel + RogaratinibCombination	Predictive	D	Supports Sensitivity Response	4	submitted	EID7831 Rogaratinib (BAY 1163877) was tested in cell line- and patient-derived models of lung cancer. DMS‐114 models, which have FGFR1 amplification and overexpression, had significantly decreased tumor volu… (full text at CIViC) PMID 30807645 · Grünewald et al., 2019 · Open in CIViC	civic

Estrogen Receptor-positive Breast Cancer1unmapped disease
FGFR1 Amplification OR FGFR1 Overexpression	Antiestrogen Therapy + CDK4/6 InhibitionCombination	Predictive	D	Supports Resistance	4	accepted	EID12557 In a cell line screen using MCF-7, exogenous expression of FGFR1 confers resistance to fulvestrant and fulvestrant plus ribociclib. In a study using breast cancer cell lines MCF-7 and T47D, overexpres… (full text at CIViC) PMID 30914635 · Formisano et al., 2019 · Open in CIViC	civic